androgen receptor splice variant, ar-v7, as prostate cancer biomarker
Published 8 years ago • 839 plays • Length 6:14Download video MP4
Download video MP3
Similar videos
-
0:42
dr. rathkopf on ar-v7 biomarker in prostate cancer
-
2:34
ar-v7 as a biomarker in crpc
-
1:01
dr. armstrong discusses ar-v7 testing in prostate cancer
-
6:29
ar-v7 and drug resistance
-
6:30
ar-v7 as a predictive marker in prostate cancer
-
1:00
dr. armstrong on the utility of ar-v7 as a biomarker in prostate cancer
-
1:32
dr. antonarakis discusses ar-v7 and response to taxanes in men with mcrpc
-
3:33
prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
-
8:28
metastatic prostate cancer: androgen receptor biology
-
4:21
case 3: clinical relevance of the ar-v7 biomarker in mcrpc
-
5:34
multidisciplinary care for prostate cancer and ar-v7 status
-
7:46
prostate cancer: validation of ar-v7 testing
-
6:56
ar-v7 testing for men with advanced stage prostate cancer
-
21:52
ar v7 predicts response in crpc
-
5:37
ar-v7 testing in mcrpc
-
29:02
ar-v7 in castration resistant prostate cancer
-
1:51
tenascin-c activated src regulates ar-v7 related to treatment resistance in prostate cancer
-
1:04
dr. emmanuel s. antonarakis on the future of the ar-v7 biomarker in prostate cancer
-
13:04
androgen receptor-targeted ttherapies in advanced prostate cancer